Reviewing Synaptogenix (NASDAQ:SNPX) and Adhera Therapeutics (OTCMKTS:ATRX)

Synaptogenix (NASDAQ:SNPX) and Adhera Therapeutics (OTCMKTS:ATRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Synaptogenix and Adhera Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	0	0	1	0	3.00
Adhera Therapeutics	0	0	0	0	0.00

Synaptogenix presently has a consensus target price of $14.00, indicating a potential upside of 351.61%. Given Synaptogenix’s stronger consensus rating and higher probable upside, equities analysts plainly believe Synaptogenix is more favorable than Adhera Therapeutics.

Profitability

This table compares Synaptogenix and Adhera Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-42.14%	-29.42%
Adhera Therapeutics	N/A	N/A	N/A

Volatility & Risk

Synaptogenix has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Adhera Therapeutics has a beta of 3.34, suggesting that its share price is 234% more volatile than the S&P 500.

Earnings & Valuation

This table compares Synaptogenix and Adhera Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	N/A	N/A	-$6.04 million	N/A	N/A
Adhera Therapeutics	N/A	N/A	-$2.11 million	N/A	N/A

Institutional and Insider Ownership

10.3% of Synaptogenix shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by company insiders. Comparatively, 28.2% of Adhera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Adhera Therapeutics beats Synaptogenix on 5 of the 9 factors compared between the two stocks.

About Synaptogenix

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

About Adhera Therapeutics

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.